Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

aducanumab-avwa

- PMLiVE

Researchers discover how neurons die in Alzheimer’s disease

The findings open up potential avenues to develop new treatments for the condition

- PMLiVE

AstraZeneca’s rare disease unit partners with Verge Genomics in deal worth over $840m

Both will identify drug targets for neurodegenerative and neuromuscular diseases

- PMLiVE

MIT study finds drug candidate reduces inflammation in Alzheimer’s models

The candidate significantly reduced inflammation and improved cognitive functions

- PMLiVE

Alzheimer’s Research UK calls on party leaders to tackle dementia pressures

One in three people living with dementia in England never receive a formal diagnosis

- PMLiVE

International survey reveals varying effects of oral medicines for Parkinson’s

More than 65% of respondents reported variations in the effects of taking oral medications

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

Study reveals gut conditions could be early sign of Parkinson’s disease

Constipation, dysphagia and IBS could be potential biomarkers of the condition

- PMLiVE

Study shows AI scans could detect Parkinson’s years before clinical presentation

OCT scans could be used by the NHS for the diagnosis of neurodegenerative diseases

- PMLiVE

Innovate UK awards Sano Genetics £330,000 grant for ALS study

The project will chart the psychological impacts of having a genetic predisposition to ALS

- PMLiVE

Alzheimer’s Research UK awards £370,000 to University of Exeter researchers

The grants are part of a wider £3m funding announcement that aims to accelerate effective treatments for dementia

- PMLiVE

Quest Diagnostics launches Alzheimer’s blood test for US consumers

Alzheimer's disease is expected to affect around 14 million people in the US by 2060

Biogen Idec building

Biogen to acquire Reata for approximately $7.3bn

The deal gives Biogen access to a recently launched therapy for Friedreich's ataxia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links